SCHEMBL1574085

SCHEMBL1574085

O=C(Oc1n[nH]c2cc(F)ccc12)N1CCN(c2ccccc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 1/20 0.54
FAAH O00519 2/20 0.46
LMNA P02545 3/20 0.45
ALDH1A1 P00352 3/20 0.45
RECQL P46063 1/20 0.45
TACR3 P29371 1/20 0.45
TSHR P16473 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
HPGD P15428 1/20 0.42
MAP2K4 P45985 2/20 0.42
DRD2 P14416 1/20 0.42
DRD4 P21917 1/20 0.42
DRD3 P35462 1/20 0.42
GRM5 P41594 1/20 0.42
MAPK1 P28482 2/20 0.41
USP2 O75604 1/20 0.41
MAPT P10636 1/20 0.41
RBP4 P02753 1/20 0.41
KIT P10721 1/20 0.41
FLT3 P36888 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4843722 0.85 KIT (0.41) ALOX15LMNAALDH1A1RECQLTACR3
SCHEMBL1574118 0.84 FLT3 (0.47) SMN1; SMN2GRM5MAPK1FLT3
SCHEMBL1574198 0.84 TP53 (0.47) TSHRSMN1; SMN2MAP2K4MAPK1TP53
SCHEMBL1573919 0.84 HRH4 (0.47) FAAHALDH1A1MAP2K4MAPK1KIT
SCHEMBL1573862 0.84 ALDH1A1 (0.44) LMNAALDH1A1TSHRSMN1; SMN2HPGD
SCHEMBL1573854 0.82 RBP4 (0.45) FAAHMAP2K4MAPK1RBP4
SCHEMBL1573920 0.82 MAP2K4 (0.41) LMNAALDH1A1SMN1; SMN2MAP2K4MAPK1
SCHEMBL1573781 0.82 MAP2K4 (0.41) ALDH1A1MAP2K4MAPK1RBP4
SCHEMBL1574209 0.81 HRH3 (0.46) MAP2K4MAPK1RBP4
SCHEMBL1573680 0.81 RBP4 (0.43) SMN1; SMN2MAP2K4MAPK1RBP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1937648-B1 DIACYL INDAZOL DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS SANOFI SA (FR) 2014-11-26 EP disclosed
US-8357698-B2 Diacyl indazole derivatives as lipase and phospholipase inhibitors SANOFI (FR) 2013-01-22 US disclosed
EP-1713779-B1 INDAZOLE DERIVATIVES AS INHIBITORS OF HORMONE-SENSITIVE LIPASES SANOFI AVENTIS DEUTSCHLAND (DE) 2011-04-13 EP disclosed
US-20100286133-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors SANOFI-AVENTIS (FR) 2010-11-11 US disclosed
US-7772268-B2 inhibitors of hormone-sensitive lipase and/or endothelial lipase; for treatment of diabetes mellitus, dyslipidemia and atherosclerotic disorders SANOFI-AVENTIS (FR) 2010-08-10 US disclosed
US-20080287448-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors SANOFI-AVENTIS (FR) 2008-11-20 US disclosed
EP-1937648-A1 DIACYL INDAZOL DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS sanofi-aventis (FR) 2008-07-02 EP disclosed
WO-2007042178-A1 DIACYL INDAZOL DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS SANOFI-AVENTIS (DE) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287448-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors PNLIP, DAGLA, MGLL ALOX15 286/4885FAAH 133/4885LMNA 1799/4885
US-20100286133-A1 Diacyl indazole derivatives as lipase and phospholipase inhibitors PNLIP, DAGLA, MGLL ALOX15 286/4885FAAH 133/4885LMNA 1799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.